Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BAM8–22 is a 15-amino acid endogenous peptide fragment derived from proenkephalin A. It acts as a potent and selective agonist for Mas-related G protein-coupled receptors (MRGPRs), specifically human MRGPRX1 and mouse MrgprC11. Unlike related peptides containing the met-enkephalin motif, BAM8–22 does not bind opioid receptors. In preclinical models, it induces scratching behavior in mice via activation of sensory neuron-specific GPCRs and is considered an endogenous pruritogen mediating histamine-independent itch in both mice and humans. Additionally, it has been shown to attenuate bone cancer pain in animal models by modulating mitochondrial function in spinal cord neurons[1][4][5][6][7][10].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on BAM8-22.